Il-6 plasmatic concentration is influenced by environmental and genetical factors, including the -174G->C and nt 565 G->A polimorphism of IL-6 promoter.
Il-6 plasmatic concentration is influenced by environmental and genetical factors, including the -174G->C and nt 565 G->A polimorphism of IL-6 promoter.
Objective: To assess the association between -174G->C and nt 565 G->A polimorphism of IL-6 promoter and short term postoperative cardiovascular risk at patients with peripheral arterial disease (PAD).
Methods:
We included 32 consecutive patients with Fontaine stage II-IV PAD proposed for nonemergent vascular surgery. We analyzed the -174G->C and nt 565 G->A polimorphism of IL-6 promoter, inflammation markers (fibrinogen, C reactive protein-CRP) and atherosclerosis risk factors (age,smoking, diabetes mellitus,hypertension,metabolic syndrome, dyslipidemia). Patients were followed for cardiovascular events (cardiac death, acute myocardial infarction, unstable angina, stroke) 30 days after surgery.
Results: Allele frequency in our group was:-174 G allele-67.25% and-174 C allele-32.75%; nt565 G allele-67.25% and nt565 A allele-32.75%. Two patients had acute cardiovascular events after surgery (6.25%); both patients with genotype -174 G/C and nt565 G/A. Inflammation markers were increased at patients with genotype-174 GG(fibrinogen-468.36±134.15 mg/dl; CRP-16.23±2.43 mg/dl) and GC(fibrinogen-478.67±121.63 mg/dl; CRP-44.47±8.77 mg/dl), versus CC genotype(fibrinogen-355.67±112.22 mg/dl; CRP-4.34±0.8 mg/dl). Also increased values of inflammation markers were present at genotype nt565 GG (fibrinogen-467.71±134.33 mg/dl; CRP-14.75±2.26 mg/dl) and GA(479.27±121.28 mg/dl; CRP-45.85±8.01 mg/dl),versus AA genotype(fibrinogen-355.67±112.22 mg/dl; CRP-4.34±0.8 mg/dl), but without statistical significance. There was no correlation between IL-6 promoter polymorphism and other atherosclerosis risk factors.
Conclusion:
Genotypes -174 G/C and nt565 G/A are associated with a high risk of short term postoperative acute cardiovascular events at patients with peripheral arterial disease undergoing a nonemergent vascular surgery.
